What drug did Dr. Andre Kalil combine with Remdesivir in his treatment approach?

Dr. Andre Kalil combined Remdesivir with Baricitinib in his treatment approach. Baricitinib is an oral Janus kinase (JAK) inhibitor that can reduce inflammation and potentially improve outcomes for patients suffering from severe viral infections such as COVID-19. The rationale behind this combination therapy is that while Remdesivir works as an antiviral drug targeting viral replication, Baricitinib addresses the inflammatory response associated with the disease. This dual action could lead to a more effective treatment profile by tackling both the virus and the inflammatory response that contributes to the severity of the illness. This combination has been associated with improved clinical outcomes in clinical trials, making it a significant contribution to COVID-19 treatment protocols.